NasdaqGM:URGN

Stock Analysis Report

Executive Summary

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has UroGen Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.8%

NasdaqGM:URGN

0.6%

US Biotechs

1.3%

US Market


1 Year Return

-21.8%

NasdaqGM:URGN

-10.3%

US Biotechs

2.0%

US Market

URGN underperformed the Biotechs industry which returned -10.8% over the past year.

URGN underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

URGNIndustryMarket
7 Day4.8%0.6%1.3%
30 Day9.9%-1.2%3.9%
90 Day-0.8%-0.1%3.4%
1 Year-21.8%-21.8%-9.5%-10.3%4.2%2.0%
3 Yearn/a7.1%3.5%47.2%37.6%
5 Yearn/a3.3%-1.7%60.5%42.9%

Price Volatility Vs. Market

How volatile is UroGen Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is UroGen Pharma undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

UroGen Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).

UroGen Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

UroGen Pharma is loss making, we can't compare its value to the US Biotechs industry average.

UroGen Pharma is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for UroGen Pharma, we can't assess if its growth is good value.


Price Based on Value of Assets

UroGen Pharma is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is UroGen Pharma expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

68.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

UroGen Pharma's revenue is expected to grow significantly at over 20% yearly.

UroGen Pharma's earnings are expected to grow significantly at over 20% yearly.

UroGen Pharma's revenue growth is expected to exceed the United States of America market average.

UroGen Pharma's earnings growth is expected to exceed the United States of America market average.

UroGen Pharma's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if UroGen Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has UroGen Pharma performed over the past 5 years?

-60.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

UroGen Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare UroGen Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare UroGen Pharma's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if UroGen Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if UroGen Pharma has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if UroGen Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is UroGen Pharma's financial position?


Financial Position Analysis

UroGen Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

UroGen Pharma's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

UroGen Pharma has no debt.

UroGen Pharma has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

UroGen Pharma has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

UroGen Pharma has sufficient cash runway for more than 3 years based on current free cash flow.

UroGen Pharma has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 99.3% each year.


Next Steps

Dividend

What is UroGen Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate UroGen Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate UroGen Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as UroGen Pharma has not reported any payouts.

Unable to verify if UroGen Pharma's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as UroGen Pharma has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of UroGen Pharma's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of UroGen Pharma's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Liz Barrett (57yo)

0.7yrs

Tenure

0

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She served as Chief Executive Officer of Novartis Oncology ...


Management Age and Tenure

1.3yrs

Average Tenure

54yo

Average Age

The average tenure for the UroGen Pharma management team is less than 2 years, this suggests a new team.


Board Age and Tenure

2.4yrs

Average Tenure

63yo

Average Age

The average tenure for the UroGen Pharma board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$10,06622 Mar 19
Mark Schoenberg
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares272
Max PriceUS$37.01
SellUS$35,39808 Mar 19
Mark Schoenberg
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares949
Max PriceUS$37.30

Ownership Breakdown


Management Team

  • Ron Bentsur (53yo)

    • Tenure: 0.7yrs
    • Compensation: US$5.95m
  • Gary Titus (59yo)

    Consultant

    • Tenure: 1.3yrs
    • Compensation: US$3.49m
  • Stephen Mullennix

    Chief Operating Officer

    • Tenure: 1.6yrs
    • Compensation: US$4.31m
  • Mark Schoenberg (61yo)

    Chief Medical Officer

    • Tenure: 1.8yrs
    • Compensation: US$300.00k
  • Elyse Seltzer (54yo)

    Senior Vice President of Clinical Development

    • Tenure: 1.8yrs
  • Peter Pfreundschuh (50yo)

    CFO & Secretary

    • Tenure: 1.1yrs
    • Compensation: US$2.49m
  • Liz Barrett (57yo)

    President

    • Tenure: 0.7yrs
  • Sari Prutchi-Sagiv

    Marketing Director

    • Tenure: 0yrs
  • Gil Hakim (49yo)

    Consultant

    • Tenure: 1.1yrs
    • Compensation: US$3.86m
  • Kate Bechtold

    Director of Corporate Communications & Investor Relations

    • Tenure: 1.7yrs

Board Members

  • Kate Falberg (58yo)

    Director

    • Tenure: 2.4yrs
    • Compensation: US$540.33k
  • Fred Cohen (63yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$525.33k
  • Cindy Butitta (65yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$540.96k
  • Stuart Holden (76yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$527.83k
  • Arie Belldegrun (70yo)

    Chairman of the Board

    • Tenure: 16.8yrs
    • Compensation: US$1.98m
  • Ran Nussbaum (46yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$525.41k
  • Jack Baniel

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Liz Barrett (57yo)

    President

    • Tenure: 0.7yrs
  • Herbert Lepor

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Fred Witjes

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

UroGen Pharma Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: UroGen Pharma Ltd.
  • Ticker: URGN
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$735.185m
  • Shares outstanding: 20.90m
  • Website: https://www.urogen.com

Number of Employees


Location

  • UroGen Pharma Ltd.
  • 499 Park Avenue
  • New York
  • New York
  • 10014
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
URGNNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMay 2017
UR8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2017
0XODLSE (London Stock Exchange)YesOrdinary SharesGBUSDMay 2017

Biography

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company’s lead product candidates, UGN-101 and UGN-102 are proprietary  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:28
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.